Intracranial self-stimulation to evaluate abuse potential of drugs

Pharmacological Reviews

Volumn 66, Issue 3, 2014, Pages 869-917

  Stevens Negus, S ^a   Miller, Laurence L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; CANNABINOID RECEPTOR; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG VEHICLE; FATTY ACID AMIDASE INHIBITOR; GLUTAMATE RECEPTOR; GLUTAMIC ACID DERIVATIVE; LIGAND; MONOAMINE DERIVATIVE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR; OPIATE; TESTOSTERONE; TRIPELENNAMINE; TRIPLE REUPTAKE INHIBITOR;

ACUTE DRUG ADMINISTRATION; ARTICLE; BRAIN DEPTH STIMULATION; CHRONIC DRUG ADMINISTRATION; DATA ANALYSIS; DEPENDENT VARIABLE; DEPRESSION; DRUG ABUSE; DRUG EFFECT; DRUG EXPOSURE; DRUG SELF ADMINISTRATION; ELECTRODE IMPLANT; EXPERIMENTAL BEHAVIORAL TEST; EXPERIMENTAL DESIGN; FACILITATION; FOOD DEPRIVATION; GENDER; GENE EXPRESSION; GENE TARGETING; GENETIC STRAIN; HUMAN; INTRACRANIAL SELF STIMULATION; LATENT PERIOD; LATERAL HYPOTHALAMUS; MEDIAL FOREBRAIN BUNDLE; MONOAMINE RELEASE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NOCICEPTIVE STIMULATION; NONHUMAN; PAIN; PARALYSIS; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROBABILITY; REINFORCEMENT; SEDATION; SENSORIMOTOR INTEGRATION; SEX; STRESS; ADDICTION; ANIMAL; BRAIN; ELECTRODE; ELECTROSTIMULATION; INSTRUMENTAL CONDITIONING; METABOLISM; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY; SELF STIMULATION; SENSITIVITY AND SPECIFICITY;

ANIMALS; BRAIN; CONDITIONING, OPERANT; ELECTRIC STIMULATION; ELECTRODES; HUMANS; MEDIAL FOREBRAIN BUNDLE; SELF ADMINISTRATION; SELF STIMULATION; SENSITIVITY AND SPECIFICITY; SUBSTANCE-RELATED DISORDERS;

EID: 84904416815     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.112.007419     Document Type: Article

References (410)

1. Adams WJ, Lorens SA, and Mitchell CL (1972) Morphine enhances lateral hypothalamic self-stimulation in the rat. Proc Soc Exp Biol Med140:770-771.
2. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, and Smith SE, et al. (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol16:411-420.
3. Altarifi AA, Miller LL, and Negus SS (2012) Role ofm-opioid receptor reserve and m-agonist efficacy as determinants of the effects of m-agonists on intracranial selfstimulation in rats. Behav Pharmacol23:678-692.
4. Altarifi AA and Negus SS (2011) Some determinants of morphine effects on intracranial self-stimulation in rats: dose, pretreatment time, repeated treatment, and rate dependence. Behav Pharmacol22:663-673.
5. Altarifi AA, Rice KC, and Negus SS (2013) Abuse-related effects ofm-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure. Behav Pharmacol24:459-470.
6. Antoniou K, Galanopoulos A, Vlachou S, Kourouli T, Nahmias V, Thermos K, Panagis G, Daifoti Z, Marselos M, and Papahatjis D, et al. (2005) Behavioral pharmacological properties of a novel cannabinoid 19,19-dithiolane delta8-THC analog, AMG-3. Behav Pharmacol16:499-510.
7. Arnold JC, Hunt GE, and McGregor IS (2001) Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. Life Sci70:97-108.
8. Ator NA and Griffiths RR (2003) Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend70(3, Suppl)S55-S72.
9. Baik JH (2013) Dopamine signaling in reward-related behaviors. Front Neural Circuits7:152.
10. Baldessarini RJ (2006) Drug therapy of depression and anxiety disorders, inGoodman and Gilman's The Pharmacological Basis of Therapeutics,11th ed (Brunton L, Lazo J, and Parker K, eds) pp 429-459, McGraw-Hill, New York.
11. Baldessarini RJ and Tarazi FI (2006) Pharmacotherapy of psychosis and mania, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed (Brunton L, Lazo J, and Parker K, eds) pp 461-500, McGraw-Hill, New York.
12. Baldo BA, Jain K, Veraldi L, Koob GF, and Markou A (1999) A dopamine D1 agonist elevates self-stimulation thresholds: comparison to other dopamine-selective drugs. Pharmacol Biochem Behav62:659-672.
13. Balster RL and Bigelow GE (2003) Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend70(3, Suppl) S13-S40.
14. Banks ML, Bauer CT, Blough BE, Rothman RB, Partilla JS, Baumann MH, and Negus SS (2014) Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys. Exp Clin Psychopharmacol, in press.
15. Barr AM, Song C, Sawada K, Young CE, Honer WG, and Phillips AG (2003) Tolerance to the anhedonic effects of lipopolysaccharide is associated with changes in syntaxin immunoreactivity in the nucleus accumbens. Int J Neuropsychopharmacol 6:23-34.
16. Bauco P and Wise RA (1994) Potentiation of lateral hypothalamic and midline mesencephalic brain stimulation reinforcement by nicotine: examination of repeated treatment. J Pharmacol Exp Ther271:294-301.
17. Bauer CT, Banks ML, Blough BE, and Negus SS (2013a) Rate-dependent effects of monoamine releasers on intracranial self-stimulation in rats: implications for abuse liability assessment. Behav Pharmacol24:448-458.
18. Bauer CT, Banks ML, Blough BE, and Negus SS (2013b) Use of intracranial selfstimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. Br J Pharmacol168:850-862.
19. Bauer CT, Banks ML, and Negus SS (2014) The effect of chronic amphetamine treatment on cocaine-induced facilitation of intracranial self-stimulation in rats. Psychopharmacology (Berl)doi: 10.1007/s00213-013-3405-1.
20. Baumann MH, Partilla JS, and Lehner KR (2013a) Psychoactive"bath salts": not so soothing. Eur J Pharmacol698:1-5.
21. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, and Sitte HH, et al. (2013b) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology38:552-562.
22. Bauzo RM and Bruijnzeel AW (2012) Animal models of nicotine withdrawal: intracranial self-stimulation and somatic signs of withdrawal. Methods Mol Biol829: 257-268.
23. Beardsley PM and Balster RL (1992) The intravenous self-administration of antihistamines by rhesus monkeys. Drug Alcohol Depend30:117-126.
24. Belluzzi JD and Stein L (1977) Enkephalin may mediate euphoria and drivereduction reward. Nature266:556-558.
25. BeMent SL and Ranck JB Jr (1969) A quantitative study of electrical stimulation of central myelinated fibers. Exp Neurol24:147-170.
26. Benaliouad F, Kapur S, and Rompré PP (2007) Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. Neuropsychopharmacology32:551-561.
27. Benarroch EE (2012) GABABreceptors: structure, functions, and clinical implications. Neurology78:578-584.
28. Bermudez-Rattoni F, Cruz-Morales S, and Reid LD (1983) Addictive agents and intracranial stimulation (ICS): novel antagonists and agonists of morphine and pressing for ICS. Pharmacol Biochem Behav18:777-784.
29. Bespalov A, Dravolina O, Belozertseva I, Adamcio B, and Zvartau E (2006) Lowered brain stimulation reward thresholds in rats treated with a combination of caffeine and N-methyl-D-aspartate but not alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate or metabotropic glutamate receptor-5 receptor antagonists. Behav Pharmacol17:295-302.
30. Bespalov A, Lebedev A, Panchenko G, and Zvartau E (1999) Effects of abused drugs on thresholds and breaking points of intracranial self-stimulation in rats. Eur Neuropsychopharmacol9:377-383.
31. Bespalov A, Sukhotina I, Medvedev I, Malyshkin A, Belozertseva I, Balster R, and Zvartau E (2003) Facilitation of electrical brain self-stimulation behavior by abused solvents. Pharmacol Biochem Behav75:199-208.
32. Bishop MP, Elder ST, and Heath RG (1963) Intracranial self-stimulation in man. Science140:394-396.
33. Blokhina EA, Dravolina OA, Bespalov AY, Balster RL, and Zvartau EE (2004) Intravenous self-administration of abused solvents and anesthetics in mice. Eur J Pharmacol485:211-218.
34. Bonano JS, Glennon RA, De Felice LJ, Banks ML, and Negus SS (2014) Abuserelated and abuse-limiting effects of methcathinone and the synthetic"bath salts" cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. Psychopharmacology (Berl)231: 199-207.
35. Borowski T, Kokkinidis L, Merali Z, and Anisman H (1998) Lipopolysaccharide, central in vivo biogenic amine variations, and anhedonia. Neuroreport9: 3797-3802.
36. Borowski TB and Kokkinidis L (1992) Long-term influence of d-amphetamine on mesolimbic brain-stimulation reward: comparison to chronic haloperidol and naloxone effects. Pharmacol Biochem Behav43:1-15.
37. Bossert JM and Franklin KB (2003) Reinforcing versus anticonvulsant drugs: effects on intracranial self-stimulation rate-frequency M50 indices. Behav Brain Res144: 243-247.
38. Bozarth MA, Pudiak CM, and KuoLee R (1998) Effect of chronic nicotine on brain stimulation reward. II. An escalating dose regimen. Behav Brain Res96:189-194.
39. Bradbury S, Bird J, Colussi-Mas J, Mueller M, Ricaurte G, and Schenk S (2013) Acquisition of MDMA self-administration: pharmacokinetic factors and MDMAinduced serotonin release. Addict Bioldoi: 10.1111/adb.12069.
40. Brady JV, Boren JJ, Conrad D, and Sidman M (1957) The effect of food and water deprivation upon intracranial self-stimulation. J Comp Physiol Psychol50: 134-137.
41. Brady JV and Griffiths RR (1976) Behavioral procedures for evaluating the relative abuse potential of CNS drugs in primates. Fed Proc35:2245-2253.
42. Broekkamp CL, Van den Bogaard JH, Heijnen HJ, Rops RH, Cools AR, and Van Rossum JM (1976) Separation of inhibiting and stimulating effects of morphine on self-stimulationbehaviour by intracerebral microinjections. Eur J Pharmacol36: 443-446.
43. Bruijnzeel AW, Bishnoi M, van Tuijl IA, Keijzers KF, Yavarovich KR, Pasek TM, Ford J, Alexander JC, and Yamada H (2010) Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats. Psychopharmacology (Berl)212:485-499.
44. Bubser M, Byun N, Wood MR, and Jones CK (2012) Muscarinic receptor pharmacology and circuitry for the modulation of cognition. Handb Exp Pharmacol208: 121-166.
45. Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK, Gross AL, Kroes RA, and Moskal JR (2013) GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketaminelike side effects. Neuropsychopharmacology38:729-742.
46. Cabeza de Vaca S and Carr KD (1998) Food restriction enhances the central rewarding effect of abused drugs. J Neurosci18:7502-7510.
47. Cabeza de Vaca S, Krahne LL, and Carr KD (2004) A progressive ratio schedule of self-stimulation testing in rats reveals profound augmentation of d-amphetamine reward by food restriction but no effect of a"sensitizing"regimen of d-amphetamine. Psychopharmacology (Berl)175:106-113.
48. Caggiula AR and Hoebel BG (1966)"Copulation-reward site"in the posterior hypothalamus. Science153:1284-1285.
49. Caille S, Clemens K, Stinus L, and Cador M (2012) Modeling nicotine addiction in rats. Methods Mol Biol829:243-256.
50. Caine SB, Bowen CA, Yu G, Zuzga D, Negus SS, and Mello NK (2004) Effect of gonadectomy and gonadal hormone replacement on cocaine self-administration in female and male rats. Neuropsychopharmacology29:929-942.
51. Caine SB and Koob GF (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science260:1814-1816.
52. Carey RJ, Goodall EB, and Procopio GF (1974) Differential effects of d-amphetamine on fixed ratio 30 performance maintained by food versus brain stimulation reinforcement. Pharmacol Biochem Behav2:193-198.
53. Carlezon WA Jr, Béguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY, and Cohen BM (2006) Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther316:440-447.
54. Carlezon WA Jr and Chartoff EH (2007) Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc2:2987-2995.
55. Carlezon WA Jr and Wise RA (1993a) Morphine-induced potentiation of brain stimulationreward is enhanced by MK-801. Brain Res620:339-342.
56. Carlezon WA Jr and Wise RA (1993b) Phencyclidine-induced potentiation of brain stimulation reward: acute effects are not altered by repeated administration. Psychopharmacology (Berl)111:402-408.
57. Carr KD, Kim GY, and Cabeza de Vaca S (2001) Rewarding and locomotor-activating effects of direct dopamine receptor agonists are augmented by chronic food restriction in rats. Psychopharmacology (Berl)154:420-428.
58. Carr KD, Yamamoto N, Omura M, Cabeza de Vaca S, and Krahne L (2002) Effects of the D(3) dopamine receptor antagonist, U99194A, on brain stimulation and d-amphetamine reward, motor activity, and c-fos expression in ad libitum fed and food-restricted rats. Psychopharmacology (Berl)163:76-84.
59. Carrera MR, Schulteis G, and Koob GF (1999) Heroin self-administration in dependent Wistar rats: increased sensitivity to naloxone. Psychopharmacology (Berl) 144:111-120.
60. Carter LP and Griffiths RR (2009) Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend105 (Suppl 1):S14-S25.
61. Cazala P (1976) Effects of d-and l-amphetamine on dorsal and ventral hypothalamic self-stimulation in three inbred strains of mice. Pharmacol Biochem Behav5: 505-510.
62. Cazala P, Cazals Y, and Cardo B (1974) Hypothalamic self-stimulation in three inbred strains of mice. Brain Res81:159-167.
63. Chan MH, Chung SS, Stoker AK, Markou A, and Chen HH (2012) Sarcosine attenuates toluene-induced motor incoordination, memory impairment, and hypothermia but not brain stimulation reward enhancement in mice. Toxicol Appl Pharmacol265:158-165.
64. Chaplin WF, John OP, and Goldberg LR (1988) Conceptions of states and traits: dimensional attributes with ideals as prototypes. J Pers Soc Psychol54:541-557.
65. Charney DS, Mihic SJ, and Adron Harris R (2006) Hypnotics and sedatives, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed (Brunton L, Lazo J, and Parker K, eds) pp 401-427, McGraw-Hill, New York.
66. Chavkin C (2011) The therapeutic potential ofk-opioids for treatment of pain and addiction. Neuropsychopharmacology36:369-370.
67. Cheer JF, Heien ML, Garris PA, Carelli RM, and Wightman RM (2005) Simultaneous dopamine and single-unit recordings reveal accumbens GABAergic responses: implications for intracranial self-stimulation. Proc Natl Acad Sci USA102: 19150-19155.
68. Cicero TJ, Aylward SC, and Meyer ER (2003) Gender differences in the intravenous self-administration of mu opiate agonists. PharmacolBiochem Behav74:541-549.
69. Clark AS, Lindenfeld RC, and Gibbons CH (1996) Anabolic-androgenic steroids and brain reward. Pharmacol Biochem Behav53:741-745.
70. Cleva RM, Watterson LR, Johnson MA, and Olive MF (2012) differential modulation of thresholds for intracranial self-stimulation by mGlu5 positive and negative allosteric modulators: implications for effects on drug self-administration. Front Pharmacol2:93.
71. Collins RJ, Weeks JR, Cooper MM, Good PI, and Russell RR (1984) Prediction of abuse liability of drugs using IV self-administration by rats. Psychopharmacology (Berl) 82:6-13.
72. Comer SD, Sullivan MA, Vosburg SK, Kowalczyk WJ, and Houser J (2010) Abuse liability of oxycodone as a function of pain and drug use history. Drug Alcohol Depend109:130-138.
73. Conn PJ, Jones CK, and Lindsley CW (2009) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 30:148-155.
74. Cooper ZD, Sullivan MA, Vosburg SK, Manubay JM, Haney M, Foltin RW, Evans SM, Kowalczyk WJ, Saccone PA, and Comer SD (2012) Effects of repeated oxycodone administration on its analgesic and subjective effects in normal, healthy volunteers. Behav Pharmacol23:271-279.
75. Corbett D (1989) Possible abuse potential of the NMDA antagonist MK-801. Behav Brain Res34:239-246.
76. Corbett D (1990) Differences in sensitivity to neuroleptic blockade: medial forebrain bundle versus frontal cortex self-stimulation. Behav Brain Res36:91-96.
77. Cottencin O, Rolland B, and Karila L (2013) New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Curr Pharm Des, in press.
78. Coulombe D and Miliaressis E (1987) Fitting intracranial self-stimulation data with growth models. Behav Neurosci101:209-214.
79. Craft RM, Stoffel EC, and Stratmann JA (2001) Effects of chronic morphine treatment on responding for intracranial stimulation in female versus male rats. Exp Clin Psychopharmacol9:198-208.
80. Cravatt BF and Lichtman AH (2004) The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol61:149-160.
81. Cryan JF, Hoyer D, and Markou A (2003) Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry54:49-58.
82. De Felice LJ, Glennon RA, and Negus SS (2014) Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology. Life Sci97:20-26.
83. DemeterE and Sarter M (2013) Leveraging the cortical cholinergic system to enhance attention. Neuropharmacology64:294-304.
84. Deneau G, Yanagita T, and Seevers MH (1969) Self-administration of psychoactive substances by the monkey. Psychopharmacology (Berl)16:30-48.
85. Depoortere R, Perrault G, and Sanger DJ (1996) Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology (Berl)124:231-240.
86. Der-Avakian A and Markou A (2012) The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci35:68-77.
87. Devine DP, Leone P, Pocock D, and Wise RA (1993) Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J Pharmacol Exp Ther 266:1236-1246.
88. DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, and Yuan C, et al. (2013) A G protein-biased ligand at the m-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344: 708-717
89. Dingledine R, Borges K, Bowie D, and Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev51:7-61.
90. Dinieri JA, Nemeth CL, Parsegian A, Carle T, Gurevich VV, Gurevich E, Neve RL, Nestler EJ, and Carlezon WA Jr (2009) Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response elementbinding protein function within the nucleus accumbens. J Neurosci29:1855-1859.
91. Divito CB and Underhill SM (2014) Excitatory amino acid transporters: Roles in glutamatergic neurotransmission. Neurochem Intdoi: 10.1016/j.neuint.2013.12.008.
92. Do Carmo GP, Folk JE, Rice KC, Chartoff E, Carlezon WA Jr, and Negus SS (2009) The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats. Eur J Pharmacol604:58-65.
93. Donahue RJ, Muschamp JW, Russo SJ, Nestler EJ, and Carlezon WA Jr (2014) Effects of striatalDFosB overexpression and ketamine on social defeat stressinduced anhedonia in mice. Biol Psychiatrydoi: 10.1016/j.biopsych.2013.12.014.
94. Druhan JP, Fibiger HC, and Phillips AG (1989) Differential effects of cholinergic drugs on discriminative cues and self-stimulation produced by electrical stimulation of the ventral tegmental area. Psychopharmacology (Berl)97:331-338.
95. Easterling KW and Holtzman SG (1997a) Intracranial self-stimulation in rats: sensitization to an opioid antagonist following acute or chronic treatment with mu opioid agonists. J Pharmacol Exp Ther281:188-199.
96. Easterling KW and Holtzman SG (1997b) Parametric changes in response equilibrium during an intra-cranial self stimulation (ICSS) task: can reward value be assessed independently of absolute threshold?Neurosci Biobehav Rev21:55-65.
97. Easterling KW, Plovnick RM, and Holtzman SG (2000) Acute opioid but not benzodiazepine dependence in rats responding for intracranial self-stimulation. Psychopharmacology (Berl)148:263-271.
98. Egawa K and Fukuda A (2013) Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models. Front Neural Circuits7:170.
99. Elder ST, May JG, and Rye MM (1965) Establishment and control of a bar-pressing habit by means of fixed interval ICSS reinforcement. Psychol Rep17:607-618.
100. Elmer GI, Pieper JO, Hamilton LR, and Wise RA (2010) Qualitative differences between C57BL/6J and DBA/2J mice in morphine potentiation of brain stimulation reward and intravenous self-administration. Psychopharmacology (Berl)208: 309-321.
101. Elmer GI, Pieper JO, Levy J, Rubinstein M, Low MJ, Grandy DK, and Wise RA (2005) Brain stimulation and morphine reward deficits in dopamine D2 receptordeficient mice. Psychopharmacology (Berl)182:33-44.
102. Elmer GI, Pieper JO, Rubinstein M, Low MJ, Grandy DK, and Wise RA (2002) Failure of intravenous morphine to serve as an effective instrumental reinforcer in dopamine D2 receptor knock-out mice. J Neurosci22:RC224.
103. Elsohly MA, Gul W, Wanas AS, and Radwan MM (2014) Synthetic cannabinoids: analysis and metabolites. Life Sci97:78-90.
104. EnginE, Bakhurin KI, Smith KS, Hines RM, Reynolds LM, Tang W, Sprengel R, Moss SJ, and Rudolph U (2014) Neural basis of benzodiazepine reward: requirement fora2 containing GABA receptors in the nucleus accumbens. Neuropsychopharmacologydoi: 10.1038/npp.2014.41.
105. Epping-Jordan MP, Watkins SS, Koob GF, and Markou A (1998) Dramatic decreases in brain reward function during nicotine withdrawal. Nature393:76-79.
106. Esposito R and Kornetsky C (1977) Morphine lowering of self-stimulation thresholds: lack of tolerance with long-term administration. Science195:189-191.
107. Esposito RU, Motola AH, and Kornetsky C (1978) Cocaine: acute effects on reinforcement thresholds for self-stimulation behavior to the medial forebrain bundle. Pharmacol Biochem Behav8:437-439.
108. Esposito RU, Perry W, and Kornetsky C (1980) Effects of d-amphetamine and naloxone on brain stimulation reward. Psychopharmacology (Berl)69:187-191.
109. Ettenberg A and Milner PM (1977) Effects of dopamine supersensitivity on lateral hypothalamic self-stimulation in rats. Pharmacol Biochem Behav7:507-514.
110. European Medicines Agency (2006) Guideline on the non-clinical investigation of the dependence potential of medicinal products, in (http://www.ema.europa.eu/ema/ index.jsp?curl=pages/regulation/general/general_content_000397.jsp&mid=WC0-b01ac058002956f ed).
111. Ewan EE and Martin TJ (2012) Intracranial self-stimulation of the paraventricular nucleus of the hypothalamus: increased faciliation by morphine compared to cocaine. Anesthesiology116:1116-1123.
112. Ewan EE and Martin TJ (2011) Opioid facilitation of rewarding electrical brain stimulation is suppressed in rats with neuropathic pain. Anesthesiology114: 624-632.
113. Ewan EE and Martin TJ (2013) Analgesics as reinforcers with chronic pain: Evidence from operant studies. Neurosci Lett557:60-64.
114. Ewan EE and Martin TJ (2014) Differential suppression of intracranial selfstimulation, food-maintained operant responding, and open field activitty by paw incision and spinal nerve ligation in rats. Anaesthesiologydoi: 10.1213/ ANE.0000000000000119.
115. Fantegrossi WE, Murnane KS, and Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol75:17-33.
116. Fantegrossi WE, Winger G, Woods JH, Woolverton WL, and Coop A (2005) Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend77: 161-168.
117. Farrant M and Nusser Z (2005) Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci6:215-229.
118. Fattore L, Cossu G, Martellotta CM, and Fratta W (2001) Intravenous selfadministration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology (Berl)156:410-416.
119. FentonHM and Liebman JM (1982) Self-stimulation response decrement patterns differentiate clonidine, baclofen and dopamine antagonists from drugs causing performance deficit. Pharmacol Biochem Behav17:1207-1212.
120. Fibiger HC and Phillips AG (1981) Increased intracranial self-stimulation in rats after long-term administration of desipramine. Science214:683-685.
121. Fiorino DF, Coury A, Fibiger HC, and Phillips AG (1993) Electrical stimulation of reward sites in the ventral tegmental area increases dopamine transmission in the nucleus accumbens of the rat. Behav Brain Res55:131-141.
122. Fish EW, Krouse MC, Stringfield SJ, Diberto JF, Robinson JE, and Malanga CJ (2013) Changes in sensitivity of reward and motor behavior to dopaminergic, glutamatergic, and cholinergic drugs in a mouse model of fragile X syndrome. PLoS ONE8:e77896.
123. Fish EW, Riday TT, McGuigan MM, Faccidomo S, Hodge CW, and Malanga CJ (2010) Alcohol, cocaine, and brain stimulation-reward in C57Bl6/J and DBA2/J mice. Alcohol Clin Exp Res34:81-89
124. Fish EW, Robinson JE, Krouse MC, Hodge CW, Reed C, Phillips TJ, and Malanga CJ (2012) Intracranial self-stimulation in FAST and SLOW mice: effects of alcohol and cocaine. Psychopharmacology (Berl)220:719-730.
125. Flagstad P, Arnt J, and Olsen CK (2006) Classical as well as novel antipsychotic drugs increase self-stimulation threshold in the rat-similar mechanism of action? Eur J Pharmacol544:69-76.
126. Fleming JW, McClendon KS, and Riche DM (2013) New obesity agents: lorcaserin and phentermine/topiramate. Ann Pharmacother47:1007-1016.
127. Flordellis C, Paris H, Karabinis A, and Lymperopoulos A (2004) Pharmacogenomics of adrenoceptors. Pharmacogenomics5:803-817.
128. Fokos S and Panagis G (2010) Effects of delta9-tetrahydrocannabinol on reward and anxiety in rats exposed to chronic unpredictable stress. J Psychopharmacol24: 767-777.
129. Food and Drug Administration (2010) Guidance for Industry: assessment of abuse potential of drugs (draft guidance), in http://www.fda.gov/downloads/Drugs/ and GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf.eds.
130. FowlerCD, LuQ, JohnsonPM, MarksMJ, andKennyPJ(2011)Habenulara5 nicotinic receptor subunit signalling controls nicotine intake. Nature471: 597-601.
131. Fowler CD, Tuesta L, and Kenny PJ (2013) Role of alpha5* nicotinic acetylcholine receptors in the effects of acute and chronic nicotine treatment on brain reward function in mice. Psychopharmacology (Berl)doi: 10.1007/s00213-013-3235-1.
132. Fox MA, French HT, LaPorte JL, Blackler AR, and Murphy DL (2010) The serotonin 5-HT(2A) receptor agonist TCB-2: a behavioral and neurophysiological analysis. Psychopharmacology (Berl)212:13-23.
133. Frank RA, Markou A, and Wiggins LL (1987) A systematic evaluation of the propertiesof self-stimulation train-duration response functions. Behav Neurosci101: 546-559.
134. Frank RA, Martz S, and Pommering T (1988) The effect of chronic cocaine on self-stimulation train-duration thresholds. Pharmacol Biochem Behav29:755-758.
135. Galankin T, Shekunova E, and Zvartau E (2010) Estradiol lowers intracranial selfstimulation thresholds and enhances cocaine facilitation of intracranial selfstimulation in rats. Horm Behav58:827-834.
136. Gallistel CR and Freyd G (1987) Quantitative determination of the effects of catecholaminergic agonists and antagonists on the rewarding efficacy of brain stimulation. Pharmacol Biochem Behav26:731-741.
137. Gardner EL, Paredes W, Smith D, Donner A, Milling C, Cohen D, and Morrison D (1988) Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol. Psychopharmacology (Berl)96:142-144.
138. Gilliss B, Malanga CJ, Pieper JO, and Carlezon WA Jr (2002) Cocaine and SKF-82958 potentiate brain stimulation reward in Swiss-Webster mice. Psychopharmacology (Berl)163:238-248.
139. Glick SD and Cox RS (1975) Self-admimistration of haloperidol in rats. Life Sci16: 1041-1045.
140. Glick SD and Guido RA (1982) Scopolamine self-administration: cholinergic involvement in reward mechanisms. Life Sci31:909-913.
141. Golembiowska K, Kowalska M, and Bymaster FP (2012) Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. Synapse66:435-444.
142. Goodall EB and Carey RJ (1975) Effects of d-versus l-amphetamine, food deprivation, and current intensity on self-stimulation of the lateral hypothalamus, substantia nigra, and medial frontal cortex of the rat. J Comp Physiol Psychol89: 1029-1045.
143. Grech DM, Spealman RD, and Bergman J (1996) Self-administration of D1 receptor agonists by squirrel monkeys. Psychopharmacology (Berl)125:97-104.
144. Green AS and Grahame NJ (2008) Ethanol drinking in rodents: is free-choice drinking related to the reinforcing effects of ethanol?Alcohol42:1-11.
145. Greenshaw AJ (1993) Differential effects of ondansetron, haloperidol and clozapine on electrical self-stimulation of the ventral tegmental area. Behav Pharmacol4: 479-485.
146. Griffiths RR and Chausmer AL (2000) Caffeine as a model drug of dependence: recent developments in understanding caffeine withdrawal, the caffeine dependence syndrome, and caffeine negative reinforcement. Nihon Shinkei Seishin Yakurigaku Zasshi20:223-231.
147. GriffithsRR and Johnson MW (2005) Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry66(Suppl 9):31-41.
148. Griffiths RR, Lamb RJ, Sannerud CA, Ator NA, and Brady JV (1991) Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology (Berl)103:154-161.
149. Griffiths RR, Sannerud CA, Ator NA, and Brady JV (1992) Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J Pharmacol Exp Ther260:1199-1208.
150. Griffiths RR and Woodson PP (1988) Reinforcing properties of caffeine: studies in humans and laboratory animals. Pharmacol Biochem Behav29:419-427.
151. Gutstein H and Akil H (2006) Opioid analgesics, inGoodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed (Brunton L, Lazo J, and Parker K, eds) pp 547-590, McGraw-Hill, New York.
152. Hall FS, Stellar JR, and Kelley AE (1990) Acute and chronic desipramine treatment effects on rewarding electrical stimulation of the lateral hypothalamus. Pharmacol Biochem Behav37:277-281.
153. Hariz MI, Blomstedt P, and Zrinzo L (2010) Deep brain stimulation between 1947 and 1987: the untold story. Neurosurg Focus29:E1.
154. Harris AC, Stepanov I, Pentel PR, and Lesage MG (2012) Delivery of nicotine in an extract of a smokeless tobacco product reduces its reinforcement-attenuating and discriminative stimulus effects in rats. Psychopharmacology (Berl)220:565-576.
155. Harrison AA, Gasparini F, and Markou A (2002) Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology (Berl)160:56-66.
156. Harrison AA and Markou A (2001) Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors. J Pharmacol Exp Ther297:316-325.
157. Harrison AA, Parsons LH, Koob GF, and Markou A (1999) RU 24969, a 5-HT1A/1B agonist, elevates brain stimulation reward thresholds: an effect reversed by GR 127935, a 5-HT1B/1D antagonist. Psychopharmacology (Berl)141:242-250.
158. Hatcher JP, Boyland P, and Hagan JJ (1995) The 5-HT3 receptor antagonists, granisetron and ondansetron, do not affect cocaine-induced shifts in intra-cranial self-stimulation thresholds. J Psychopharmacol9:342-347.
159. Hatcher JP and Hagan JJ (1998) The effects of dopamine D3/D2 receptor agonists on intracranial self stimulation in the rat. Psychopharmacology (Berl)140:405-410.
160. Hayes DJ, Clements R, and Greenshaw AJ (2009) Effects of systemic and intranucleus accumbens 5-HT2C receptor compounds on ventral tegmental area selfstimulation thresholds in rats. Psychopharmacology (Berl)203:579-588.
161. Hayes DJ and Greenshaw AJ (2011) 5-HT receptors and reward-related behaviour: a review. Neurosci Biobehav Rev35:1419-1449.
162. Heath RG (1963) Electrical Self-Stimulation of the Brain in Man. Am J Psychiatry 120:571-577.
163. Heath RG(1964) Pleasure response of human subjects to direct stimulation of the brain: Physiologic and psychodynamic considerations, inThe Role of Pleasure in Behavior(Heath RG, ed) pp 219-243, Hoeber, Harper and Row, New York.
164. Heckman MA, Weil J, and Gonzalez de Mejia E (2010) Caffeine (1, 3, 7-trimethylxanthine) in foods: a comprehensive review on consumption, functionality, safety, and regulatory matters. JFoodSci75:R77-R87.
165. Herberg LJ and Rose IC (1989) The effect of MK-801 and other antagonists of NMDAtype glutamate receptors on brain-stimulation reward. Psychopharmacology (Berl) 99:87-90.
166. Herberg LJ and Rose IC (1990) Excitatory amino acid pathways in brain-stimulation reward. Behav Brain Res39:230-239.
167. HernandezG, Breton YA, Conover K, and Shizgal P (2010) At what stage of neural processing does cocaine act to boost pursuit of rewards?PLoS ONE5:e15081.
168. Higley AE, Spiller K, Grundt P, Newman AH, Kiefer SW, Xi ZX, and Gardner EL (2011) PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. J Psychopharmacol25:263-273.
169. Hillhouse TM, Porter JH, and Negus SS (2014) Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats. Psychopharmacology (Berl)doi: 10.1007/s00213-014-3451-3.
170. Hiranita T, Soto PL, Newman AH, and Katz JL (2009) Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. J Pharmacol Exp Ther329: 677-686.
171. Hodos W and Valenstein ES (1960) Motivational variables affecting the rate of behavior maintained by intracranial stimulation. J Comp Physiol Psychol53:502-508.
172. Holtzman SG (1976) Comparison of the effects of morphine, pentazocine, cyclazocine and amphetamine on intracranial self-stimulation in the rat. Psychopharmacology (Berl) 46:223-227.
173. Horton DB, Potter DM, and Mead AN (2013) A translational pharmacology approach to understanding the predictive value of abuse potential assessments. Behav Pharmacol24:410-436.
174. Hunt GE and Atrens DM (1992) Reward summation and the effects of pimozide, clonidine, and amphetamine on fixed-interval responding for brain stimulation. Pharmacol Biochem Behav42:563-577.
175. Hunt GE, Atrens DM, Chesher GB, and Becker FT (1976) Alpha-noradrenergic modulation of hypothalamic self-stimulation: studies employing clonidine, 1-phenylephrine and alpha-methyl-p-tyrosine. Eur J Pharmacol37:105-111.
176. Hunt GE, Atrens DM, and Jackson DM (1994) Reward summation and the effects of dopamine D1 and D2 agonists and antagonists on fixed-interval responding for brain stimulation. Pharmacol Biochem Behav48:853-862.
177. Huskinson SL, Naylor JE, Rowlett JK, and Freeman KB (2014) Predicting abuse potential of stimulants and other dopaminergic drugs: Overview and recommendations. Neuropharmacologydoi: 10.1016/j.neuropharm.2014.03.009.
178. Huston-Lyons D and Kornetsky C (1992) Effects of nicotine on the threshold for rewarding brain stimulation in rats. Pharmacol Biochem Behav41:755-759.
179. Huston-Lyons D, Sarkar M, and Kornetsky C (1993) Nicotine and brain-stimulation reward: interactions with morphine, amphetamine and pimozide. Pharmacol Biochem Behav46:453-457.
180. Ichimaru Y, Moriyama M, and Gomita Y (1985) Auto-titration technique using intracranial self-stimulation and effects of antianxiety drugs. Jpn J Pharmacol39: 331-338.
181. ImmadisettyK and Madura JD (2013) A review of monoamine transporter-ligand interactions. Curr Comput Aided Drug Des9:556-568.
182. Jacques S (1979) Brain stimulation and reward:"pleasure centers"after twenty-five years. Neurosurgery5:277-283.
183. Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, Bear MF, Umbricht D, Hajos M, and Potter WZ, et al. (2011) Translating glutamate: from pathophysiology to treatment. Sci Transl Med3:102mr102.
184. Jenck F, Gratton A, and Wise RA (1987) Opioid receptor subtypes associated with ventral tegmental facilitation of lateral hypothalamic brain stimulation reward. Brain Res423:34-38.
185. Johanson CE and Balster RL (1978) A summary of the results of a drug selfadministration study using substitution procedures in rhesus monkeys. Bull Narc 30:43-54.
186. Jones CK, Byun N, and Bubser M (2012) Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology37:16-42.
187. Jones JD and Comer SD (2013) A review of human drug self-administration procedures. Behav Pharmacol24:384-395.
188. Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, King AR, Redhi GH, Yasar S, and Piomelli D, et al. (2008) Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry64:930-937.
189. Kanayama G, Hudson JI, and Pope HG Jr (2010) Illicit anabolic-androgenic steroid use. Horm Behav58:111-121.
190. Karanian DA and Bahr BA (2006) Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states. Curr Mol Med 6:677-684.
191. Katsidoni V, Apazoglou K, and Panagis G (2011) Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine. Psychopharmacology (Berl)213:337-354.
192. Katsidoni V, Kastellakis A, and Panagis G (2013) Biphasic effects ofD9-tetrahydrocannabinol on brain stimulation reward and motor activity. Int J Neuropsychopharmacol 16:2273-2284.
193. Katz JL and Goldberg SR (1988) Preclinical assessment of abuse liability of drugs. Agents Actions23:18-26.
194. Katz RJ, Baldrighi G, and Roth K (1978) Appetitive determinants of self-stimulation. Behav Biol23:500-508.
195. KatzRJ and Carroll BJ (1977) Intracranial reward after Lilly 110140 (fluoxetine HCl): evidence for an inhibitory role for serotonin. Psychopharmacology (Berl)51: 189-193.
196. Kelleher RT and Morse WH (1968) Determinants of the specificity of behavioral effects of drugs. Ergeb Physiol60:1-56.
197. Kempadoo KA, Tourino C, Cho SL, Magnani F, Leinninger GM, Stuber GD, Zhang F, Myers MG, Deisseroth K, and de Lecea L, et al. (2013) Hypothalamic neurotensin projections promote reward by enhancing glutamate transmission in the VTA. J Neurosci33:7618-7626.
198. Kendler KS, Karkowski LM, and Prescott CA (1999) Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry156:837-841.
199. Kenny PJ, Chartoff E, Roberto M, Carlezon WA Jr, and Markou A (2009) NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology34:266-281.
200. Kenny PJ, Gasparini F, and Markou A (2003a) Group II metabotropic and alphaamino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther306:1068-1076.
201. Kenny PJ, Koob GF, and Markou A (2003b) Conditioned facilitation of brain reward function after repeated cocaine administration. Behav Neurosci117:1103-1107.
202. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, and Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry62:593-602.
203. Kim KM, Baratta MV, Yang A, Lee D, Boyden ES, and Fiorillo CD (2012) Optogenetic mimicry of the transient activation of dopamine neurons by natural reward is sufficient for operant reinforcement. PLoS ONE7:e33612.
204. Kimmel HL, Negus SS, Wilcox KM, Ewing SB, Stehouwer J, Goodman MM, Votaw JR, Mello NK, Carroll FI, and Howell LL (2008) Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol Biochem Behav90:453-462.
205. Kling-Petersen T, Ljung E, Wollter L, and Svensson K (1995) Effects of dopamine D3 preferring compounds on conditioned place preference and intracranial selfstimulation in the rat. J Neural Transm101:27-39.
206. Koek W, Woods JH, and Winger GD (1988) MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidinelike behavioral effects in pigeons, rats and rhesus monkeys. J Pharmacol Exp Ther 245:969-974.
207. Kofman O and Yeomans JS (1988) Cholinergic antagonists in ventral tegmentum elevate thresholds for lateral hypothalamic and brainstem self-stimulation. Pharmacol Biochem Behav31:547-559.
208. Kokkinidis L and McCarter BD (1990) Postcocaine depression and sensitization of brain-stimulation reward: analysis of reinforcement and performance effects. Pharmacol Biochem Behav36:463-471.
209. KoobGF, Spector NH, and Meyerhoff JL (1975) Effects of heroin on lever pressing for intracranial self-stimulation, food and water in the rat. Psychopharmacology (Berl) 42:231-234.
210. Koob GF and Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217-238.
211. Kornetsky C, Bain GT, Unterwald EM, and Lewis MJ (1988) Brain stimulation reward: effects of ethanol. Alcohol Clin Exp Res12:609-616.
212. Kornetsky C, Esposito RU, McLean S, and Jacobson JO (1979) Intracranial selfstimulation thresholds: a model for the hedonic effects of drugs of abuse. Arch Gen Psychiatry36:289-292.
213. Kranz GS, Kasper S, and Lanzenberger R (2010) Reward and the serotonergic system. Neuroscience166:1023-1035.
214. Kruk ZL, Cheeta S, Milla J, Muscat R, Williams JE, and Willner P (1998) Real time measurement of stimulated dopamine release in the conscious rat using fast cyclic voltammetry: dopamine release is not observed during intracranial self stimulation. J Neurosci Methods79:9-19.
215. Kucharski LT, Williams JE, and Kornetsky C (1983) The effects of levonantradol on rewarding brain stimulation thresholds in the rat. Pharmacol Biochem Behav19: 149-151.
216. Kwilasz AJ, Abdullah RA, Poklis JL, Lichtman AH, and Negus SS (2014) Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and paindepressed behavior in rats. Behav Pharmacol25:119-129.
217. Kwilasz AJ and Negus SS (2012) Dissociable effects of the cannabinoid receptor agonistsD9-tetrahydrocannabinol and CP55940 on pain-stimulated versus paindepressed behavior in rats. J Pharmacol Exp Ther343:389-400.
218. Lasagna L, Von Felsinger JM, and Beecher HK (1955) Drug-induced mood changes in man. I. Observations on healthy subjects, chronically ill patients, and postaddicts. J Am Med Assoc157:1006-1020.
219. Latz A, Bain GT, and Kornetsky C (1969) Attenuated effect of chlorpromazine on conditioned avoidance as a function of rapid acquisition. Psychopharmacology (Berl) 14:23-32.
220. Lecca D, Cacciapaglia F, Valentini V, and Di Chiara G (2006) Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration. Psychopharmacology (Berl) 188:63-74.
221. Lee K and Kornetsky C (1998) Acute and chronic fluoxetine treatment decreases the sensitivity of rats to rewarding brain stimulation. Pharmacol Biochem Behav60: 539-544.
222. Leitl MD, Onvani S, Bowers MS, Cheng K, Rice KC, Carlezon WA Jr, Banks ML, and Negus SS (2014) Pain-related depression of the mesolimbic dopamine system in rats: expression, blockade by analgesics, and role of endogenous k-opioids. Neuropsychopharmacology39:614-624.
223. Lepore M, Liu X, Savage V, Matalon D, and Gardner EL (1996) Genetic differences in delta 9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains. Life Sci58:PL365-PL372.
224. Li X, Xi ZX, and Markou A (2013) Metabotropic glutamate 7 (mGlu7) receptor: a target for medication development for the treatment of cocaine dependence. Neuropharmacology66:12-23.
225. Licata SC and Rowlett JK (2011) Self-administration of bretazenil under progressiveratio schedules: behavioral economic analysis of the role intrinsic efficacy plays in the reinforcing effects of benzodiazepines. Drug Alcohol Depend113:157-164.
226. Liebman JM and Butcher LL (1973) Effects on self-stimulation behavior of drugs influencing dopaminergic neurotransmission mechanisms. Naunyn Schmiedebergs Arch Pharmacol277:305-318.
227. Liebman JM, Hall NR, Prowse J, Gerhardt S, Noreika L, and Fenton HM (1984) Comparative effects of beta 2-adrenoceptor agonists on intracranial selfstimulation, Sidman avoidance, and motor activity in rats. Psychopharmacology (Berl) 84:336-341.
228. Lin D, Bruijnzeel AW, Schmidt P, and Markou A (2002) Exposure to chronic mild stress alters thresholds for lateral hypothalamic stimulation reward and subsequent responsiveness to amphetamine. Neuroscience114:925-933.
229. LinD, Koob GF, and Markou A (1999) Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat-interactions between the two drugs. Psychopharmacology (Berl)145:283-294.
230. Lin D, Koob GF, and Markou A (2000) Time-dependent alterations in ICSS thresholds associated with repeated amphetamine administrations. Pharmacol Biochem Behav65:407-417.
231. Lin HQ, Jackson DM, Atrens DM, Christie MJ, and McGregor IS (1997) Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation. Brain Res 744:351-357.
232. Liu J, Pan H, Gold MS, Derendorf H, and Bruijnzeel AW (2008) Effects of fentanyl dose and exposure duration on the affective and somatic signs of fentanyl withdrawal in rats. Neuropharmacology55:812-818.
233. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM, Selley DE, and Parsons LH, et al. (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol5:37-44.
234. Lorens SA and Mitchell CL (1973) Influence of morphine on lateral hypothalamic self-stimulation in the rat. Psychopharmacology (Berl)32:271-277.
235. Macey DJ, Froestl W, Koob GF, and Markou A (2001) Both GABA(B) receptor agonist and antagonists decreased brain stimulation reward in the rat. Neuropharmacology40:676-685.
236. Malanga CJ, Riday TT, Carlezon WA Jr, and Kosofsky BE (2008) Prenatal exposure to cocaine increases the rewarding potency of cocaine and selective dopaminergic agonists in adult mice. Biol Psychiatry63:214-221.
237. Mansour A, Khachaturian H, Lewis ME, Akil H, and Watson SJ (1987) Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci7:2445-2464.
238. Marcus R and Kornetsky C (1974) Negative and positive intracranial reinforcement thresholds: Effects of morphine. Psychopharmacologia (Berl)38:1-13.
239. Markou A, Hauger RL, and Koob GF (1992) Desmethylimipramine attenuates cocaine withdrawal in rats. Psychopharmacologia (Berl)109:305-314.
240. Markou A and Koob GF (1991) Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology4:17-26.
241. Markou A and Koob GF (1992) Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav51: 111-119.
242. Marquis KL and Moreton JE (1987) Animal models of intravenous phencyclinoid self-administration. PharmacolBiochem Behav27:385-389.
243. Martellotta MC, Cossu G, Fattore L, Gessa GL, and Fratta W (1998) Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience85: 327-330.
244. Mavrikaki M, Markaki E, Nomikos GG, and Panagis G (2010) Chronic WIN55,212-2 elicits sustained and conditioned increases in intracranial self-stimulation thresholds in the rat. Behav Brain Res209:114-118.
245. McCarter BD and Kokkinidis L (1988) The effects of long-term administration of antidepressant drugs on intracranial self-stimulation responding in rats. Pharmacol Biochem Behav31:243-247.
246. McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, and Nichols DE (2006) 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J Med Chem49:5794-5803.
247. Meldrum BS (2000) Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr130(4S, Suppl)1007S-1015S.
248. Miliaressis E, Emond C, and Merali Z (1991) Re-evaluation of the role of dopamine in intracranial self-stimulation using in vivo microdialysis. Behav Brain Res46:43-48.
249. Miliaressis E, Rompre PP, Laviolette P, Philippe L, and Coulombe D (1986) The curve-shift paradigm in self-stimulation. Physiol Behav37:85-91.
250. Millar NS and Gotti C (2009) Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology56:237-246.
251. Milner PM (1989) The discovery of self-stimulation and other stories. Neurosci Biobehav Rev13:61-67.
252. Miyata H, Itasaka M, Kimura N, and Nakayama K (2011) Decreases in brain reward function reflect nicotine-and methamphetamine-withdrawal aversion in rats. Curr Neuropharmacol9:63-67.
253. Möhler H (2012) The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology62:42-53.
254. Monaghan DT, Irvine MW, Costa BM, Fang G, and Jane DE (2012) Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. Neurochem Int61:581-592.
255. Mony L, Kew JN, Gunthorpe MJ, and Paoletti P (2009) Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol157:1301-1317.
256. Moreau JL, Bourson A, Jenck F, Martin JR, and Mortas P (1994) Curative effects of the atypical antidepressant mianserin in the chronic mild stress-induced anhedoniamodel of depression. J Psychiatry Neurosci19:51-56.
257. Moreau JL, Jenck F, Martin JR, Mortas P, and Haefely WE (1992) Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats. Eur Neuropsychopharmacol 2:43-49.
258. Möykkynen T and Korpi ER (2012) Acute effects of ethanol on glutamate receptors. Basic Clin Pharmacol Toxicol111:4-13.
259. Nakajima S and O'Regan NB (1991) The effects of dopaminergic agonists and antagonists on the frequency-response function for hypothalamic self-stimulation in the rat. Pharmacol Biochem Behav39:465-468.
260. Nazzaro JM, Seeger TF, and Gardner EL (1981) Morphine differentially affects ventral tegmental and substantia nigra brain reward thresholds. Pharmacol Biochem Behav14:325-331.
261. Negus SS (2004) Delta Opioids and Substance Abuse, inThe Delta Receptor (Chang K-J, Porreca F, and Woods JH, eds) pp 401-430, Marcel Dekker, Inc., New York.
262. Negus SS (2013) Expression and treatment of pain-related behavioral depression. Lab Anim (NY)42:292-300.
263. Negus SS and Dykstra LA (1989) Neural substrates mediating the reinforcing properties of opioid analgesics, inBiochemistry and Physiology of Substance Abuse, Vol. 1(Watson RW, ed) pp 211-242, CRC Press, Boca Raton.
264. Negus SS, Gatch MB, Mello NK, Zhang X, and Rice K (1998) Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys. J Pharmacol Exp Ther286:362-375.
265. Negus SS, Morrissey EM, Rosenberg M, Cheng K, and Rice KC (2010) Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats. Psychopharmacology (Berl)210:149-159.
266. Negus SS, O'Connell R, Morrissey E, Cheng K, and Rice KC (2012a) Effects of peripherally restricted kopioid receptor agonists on pain-related stimulation and depression of behavior in rats. J Pharmacol Exp Ther340:501-509.
267. Negus SS and Rice KC (2009) Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs food choice in heroin-dependent rhesus monkeys. Neuropsychopharmacology34:899-911.
268. Negus SS, Rosenberg MB, Altarifi AA, O'Connell RH, Folk JE, and Rice KC (2012b) Effects of thedopioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats. J Pain13:317-327.
269. NegusSS, Schrode K, and Stevenson GW (2008) Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability. Exp Clin Psychopharmacol16:386-399.
270. Neill DB, Fenton H, and Justice JB Jr (2002) Increase in accumbal dopaminergic transmission correlates with response cost not reward of hypothalamic stimulation. Behav Brain Res137:129-138.
271. Neisewander JL, Peartree NA, and Pentkowski NS (2012) Emotional valence and context of social influences on drug abuse-related behavior in animal models of social stress and prosocial interaction. Psychopharmacology (Berl)224:33-56.
272. Nestler EJ and Carlezon WA Jr (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry59:1151-1159.
273. Nicholson KL, Balster RL, Golembiowska K, Kowalska M, Tizzano JP, Skolnick P, and Basile AS (2009) Preclinical evaluation of the abuse potential of the analgesic bicifadine. J Pharmacol Exp Ther330:236-248.
274. Nicholson KL, Jones HE, and Balster RL (1998) Evaluation of the reinforcing and discriminative stimulus properties of the low-affinityN-methyl-D-aspartate channel blocker memantine. Behav Pharmacol9:231-243.
275. Nielsen CK, Arnt J, and Sánchez C (2000) Intracranial self-stimulation and sucrose intake differ as hedonic measures following chronic mild stress: interstrain and interindividual differences. Behav Brain Res107:21-33.
276. Nieuwenhuys R, Geeraedts LM, and Veening JG (1982) The medial forebrain bundle of the rat. I. General introduction. J Comp Neurol206:49-81.
277. Niphakis MJ, Johnson DS, Ballard TE, Stiff C, and Cravatt BF (2012) O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem Neurosci3:418-426.
278. Nutt D, King LA, Saulsbury W, and Blakemore C (2007) Development of a rational scale to assess the harm of drugs of potential misuse. Lancet369:1047-1053.
279. O'Brien CP (2006) Drug addiction and drug abuse, inGoodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed (Brunton L, Lazo J, and Parker K, eds) pp 607-628, McGraw-Hill, New York.
280. O'Connor EC, Chapman K, Butler P, and Mead AN (2011) The predictive validity of the rat self-administration model for abuse liability. Neurosci Biobehav Rev35: 912-938.
281. O'Neill KS and Todtenkopf MS (2010) Using a rate-frequency curve method to assess the rewarding properties of morphine in the intracranial self-stimulation paradigm in rats. J Neurosci Methods189:75-79.
282. Olds J (1958a) Effects of hunger and male sex hormone on self-stimulation of the brain. J Comp Physiol Psychol51:320-324.
283. Olds J (1958b) Self-stimulation of the brain; its use to study local effects of hunger, sex, and drugs. Science127:315-324.
284. Olds J and Milner P (1954) Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol47:419-427.
285. Olds J and Travis RP (1960) Effects of chlorpromazine, meprobamate, pentobarbital and morphine on self-stimulation. J Pharmacol Exp Ther128:397-404.
286. Olds ME (1966) Facilitatory action of diazepam and chloridiazepoxide on hypothalamic reward behavior. J Comp Physiol Psychol62:136-140.
287. Olds ME (1972) Comparative effects of amphetamine, scopolamine and chlordiazepoxide on self-stimulation behavior. Rev Can Biol31(Suppl):25-47.
288. Olds ME (1995) Dopamine agonists prevent or counteract the suppression of brain stimulation reward by fenfluramine. Pharmacol Biochem Behav50:41-48.
289. Olds ME and Domino EF (1969) Comparison of muscarinic and nicotinic cholinergic agonists on self-stimulation behavior. J Pharmacol Exp Ther166:189-204.
290. Osikowicz M, Mika J, and Przewlocka B (2013) The glutamatergic system as a target for neuropathic pain relief. Exp Physiol98:372-384.
291. Palazzolo DL (2013) Electronic cigarettes and vaping: A new challenge in clinical medicine and public health. A literature review. Front Public Health1:56.
292. Panagis G, Kastellakis A, Spyraki C, and Nomikos G (2000) Effects of methyllycaconitine (MLA), an alpha 7 nicotinic receptor antagonist, on nicotine-and cocaine-induced potentiation of brain stimulation reward. Psychopharmacology (Berl) 149:388-396.
293. Panagis G, Vlachou S, and Nomikos GG (2008) Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependenceproducing properties. Curr Drug Abuse Rev1:350-374.
294. Panlilio LV, Justinova Z, and Goldberg SR (2010) Animal models of cannabinoid reward. Br J Pharmacol160:499-510.
295. Paterson NE, Bruijnzeel AW, Kenny PJ, Wright CD, Froestl W, and Markou A (2005) Prolonged nicotine exposure does not alter GABA(B) receptor-mediated regulation of brain reward function. Neuropharmacology49:953-962.
296. Paterson NE, Myers C, and Markou A (2000) Effects of repeated withdrawal from continuous amphetamine administration on brain reward function in rats. Psychopharmacology (Berl)152:440-446.
297. Paterson NE, Vlachou S, Guery S, Kaupmann K, Froestl W, and Markou A (2008) Positive modulation of GABA(B) receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats. J Pharmacol Exp Ther326:306-314.
298. Pereira Do Carmo G, Stevenson GW, Carlezon WA, and Negus SS (2009) Effects of pain-and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior. Pain144:170-177.
299. Phillips AG, Blaha CD, and Fibiger HC (1989) Neurochemical correlates of brainstimulation reward measured by ex vivo and in vivo analyses. Neurosci Biobehav Rev13:99-104.
300. Pilc A, Chaki S, Nowak G, and Witkin JM (2008) Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol75:997-1006.
301. Potter DN, Damez-Werno D, Carlezon WA Jr, Cohen BM, and Chartoff EH (2011) Repeated exposure to thek-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol Psychiatry70: 744-753.
302. Pradhan AA, Befort K, Nozaki C, Gavériaux-Ruff C, and Kieffer BL (2011) The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci32:581-590.
303. Prins J, Kenny PJ, Doomernik I, Schreiber R, Olivier B, and Mechiel Korte S (2012) The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats. Eur J Pharmacol693:51-56.
304. Rada PV, Mark GP, Yeomans JJ, and Hoebel BG (2000) Acetylcholine release in ventral tegmental area by hypothalamic self-stimulation, eating, and drinking. Pharmacol Biochem Behav65:375-379.
305. Rady JJ, Takemori AE, Portoghese PS, and Fujimoto JM (1994) Supraspinal delta receptor subtype activity of heroin and 6-monoacetylmorphine in Swiss Webster mice. Life Sci55:603-609.
306. RamôaCP, Doyle SE, Naim DW, and Lynch WJ (2013) Estradiol as a mechanism for sex differences in the development of an addicted phenotype following extended access cocaine self-administration. Neuropsychopharmacology38:1698-1705.
307. Ranaldi R and Beninger RJ (1994) The effects of systemic and intracerebral injections of D1 and D2 agonists on brain stimulation reward. Brain Res651:283-292.
308. Rasmussen T and Fink-Jensen A (2000) Intravenous scopolamine is potently selfadministered in drug-naive mice. Neuropsychopharmacology22:97-99.
309. Reavill C, Hatcher JP, Lewis VA, Sanger GJ, and Hagan J (1998) 5-HT4 receptor antagonism does not affect motor and reward mechanisms in the rat. Eur J Pharmacol357:115-120.
310. Reid LD (1987) Tests involving pressing for intracranial stimulation as an early procedure for screening the likelihood of addiction of opioids and other drugs, in Methods of Assessing the Reinforcing Properties of Abused Drugs(Bozarth MJ, ed) pp 391-420, Springer, Berlin.
311. Reid LD, Gibson WE, Gledhill SM, and Porter PB (1964) Anticonvulsant drugs and self-stimulating behavior. J Comp Physiol Psychol57:353-356.
312. Reissig CJ, Strain EC, and Griffiths RR (2009) Caffeinated energy drinks-a growing problem. Drug Alcohol Depend99:1-10.
313. Reynolds LM, Engin E, Tantillo G, Lau HM, Muschamp JW, Carlezon WA Jr, and Rudolph U (2012) Differential roles of GABA(A) receptor subtypes in benzodiazepine-induced enhancement of brain-stimulation reward. Neuropsychopharmacology37:2531-2540.
314. Richardson NR and Roberts DC (1996) Progressive ratio schedules in drug selfadministration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods66:1-11.
315. Richardson NR, Smith AM, and Roberts DCS (1994) A single injection of either flupenthixol decanoate or haloperidol decanoate produces long-term changes in cocaine self-administration in rats. Drug Alcohol Depend36:23-25.
316. Riday TT, Kosofsky BE, and Malanga CJ (2012) The rewarding and locomotorsensitizing effects of repeated cocaine administration are distinct and separable in mice. Neuropharmacology62:1858-1866.
317. Risinger FO, Brown MM, Doan AM, and Oakes RA (1998) Mouse strain differences in oral operant ethanol reinforcement under continuous access conditions. Alcohol Clin Exp Res22:677-684.
318. Risinger FO, Malott DH, Prather LK, Niehus DR, and Cunningham CL (1994) Motivational properties of ethanol in mice selectively bred for ethanol-induced locomotor differences. Psychopharmacology (Berl)116:207-216.
319. Robertson A, Laferrière A, and Franklin KB (1981) Amphetamine and increases in current intensity modulate reward in the hypothalamus and substantia nigra but not in the prefrontal cortex. PhysiolBehav26:809-813.
320. Robinson JE, Agoglia AE, Fish EW, Krouse MC, and Malanga CJ (2012) Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6J mice: comparison to cocaine. Behav Brain Res234:76-81.
321. Rocha BA (2013) Principles of assessment of abuse liability: US legal framework and regulatory environment. Behav Pharmacol24:403-409.
322. Rolls ET, Burton MJ, and Mora F (1980) Neurophysiological analysis of brainstimulation reward in the monkey. Brain Res194:339-357.
323. Rosenberg MB, Carroll FI, and Negus SS (2013) Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats. J Pain14:246-259.
324. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, and Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse39:32-41.
325. Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, and Baumann MH (2005) Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther313:1361-1369.
326. Roybal K, Theobold D, Graham A, DiNieri JA, Russo SJ, Krishnan V, Chakravarty S, Peevey J, Oehrlein N, and Birnbaum S, et al. (2007) Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci USA104:6406-6411.
327. Russell SE, Rachlin AB, Smith KL, Muschamp J, Berry L, Zhao Z, and Chartoff EH (2013) Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats. Biol PsychiatryDOI: 10.1016/j.biopsych.2013.07.042.
328. Russo SJ and Nestler EJ (2013) The brain reward circuitry in mood disorders. Nat Rev Neurosci14:609-625.
329. SAMHSA (2012) Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, in http://www.samhsa.gov/data/NSDUH/2k11Results/ NSDUHresults2011.htm#2017.2011, Substance Abuse and Mental Health Services Administration, Rockville, MD.
330. SAMHSA (2013) Drug Abuse Warning Network, 2011: National Estimates of DrugRelated Emergency Department Visits, in http://www.samhsa.gov/data/2k13/ DAWN12k11ED/DAWN12k11ED.htm, Substance Abuse and Mental Health Services Administration, Rockville, MD.
331. Sanders-Bush E and Mayer SE (2006) 5Hydroxytryptamine (serotonin): receptor agonists and antagonists, inGoodman and Gilman's The Pharmacological Basis of Therapeutics,11thed(BruntonL, LazoJ, andParkerK, eds)pp297-315, McGraw-Hill, New York.
332. Sanger DJ and Blackman DE (1976) Rate-dependent effects of drugs: a review of the literature. Pharmacol Biochem Behav4:73-83.
333. Sarter M, Parikh V, and Howe WM (2009) nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem Pharmacol78:658-667.
334. Schaefer GJ and Michael RP (1992) Interactions between alcohol and nicotine on intracranial self-stimulation and locomotor activity in rats. Drug Alcohol Depend 30:37-47.
335. SchenkS (2009) MDMA self-administration in laboratory animals: a summary of the literature and proposal for future research. Neuropsychobiology60:130-136.
336. Schlaepfer TE, Bewernick BH, Kayser S, Hurlemann R, and Coenen VA (2014) Deep brain stimulation of the human reward system for major depression-rationale, outcomes and outlook. Neuropsychopharmacology39:1303-1314.
337. Schulteis G, Markou A, Gold LH, Stinus L, and Koob GF (1994) Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis. J Pharmacol Exp Ther271:1391-1398.
338. Seeger TF, Carlson KR, and Nazzaro JM (1981a) Pentobarbital induces a naloxonereversible decrease in mesolimbic self-stimulation threshold. Pharmacol Biochem Behav15:583-586.
339. Seeger TF, Gardner EL, and Bridger WF (1981b) Increase in mesolimbic electrical self-stimulation after chronic haloperidol: reversal by L-DOPA or lithium. Brain Res215:404-409.
340. Shearman GT, Hynes M, and Lal H (1981) Self-administration of clonidine by the rat. Prog Clin Biol Res71:259-276.
341. Shizgal P and Murry B (1989) Neuronal basis of intracranial self-stimulation, inThe Neuropharmacological Basis of Reward(Liebman JM and Cooper SJ, eds) Oxford University Press, New York.
342. Singh J, Desiraju T, and Raju TR (1996) Dose-response functions of apomorphine, SKF 38393, LY 171555, haloperidol and clonidine on the self-stimulation evoked from lateral hypothalamus and ventral tegmentum. Indian J Physiol Pharmacol 40:15-22.
343. Skinner BF (1950) Are theories of learning necessary?Psychol Rev57:193-216.
344. Skinner BF (1953a)Science and Human Behavior, Macmillan, New York.
345. Skinner BF (1953b) Some contributions of an experimental analysis of behavior to psychology as a whole. Am Psychol8:69-78.
346. Skolnick P, Popik P, Janowsky A, Beer B, and Lippa AS (2003) Antidepressant-like actions of DOV 21,947: a"triple" reuptake inhibitor. Eur J Pharmacol461: 99-104.
347. Slattery DA, Markou A, and Cryan JF (2007) Evaluation of reward processes in an animal model of depression. Psychopharmacology (Berl)190:555-568.
348. Slattery DA, Markou A, Froestl W, and Cryan JF (2005) The GABABreceptorpositive modulator GS39783 and the GABABreceptor agonist baclofen attenuate the reward-facilitating effects of cocaine: intracranial self-stimulation studies in the rat. Neuropsychopharmacology30:2065-2072.
349. Spiller K, Xi ZX, Li X, Ashby CR Jr, Callahan PM, Tehim A, and Gardner EL (2009) Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats. Neuropharmacology57:60-66.
350. Spragg SDS (1940) Morphine addiction in chimpanzees. Comp Psychol Mono15: 5-132.
351. Standaert DG and Young AB (2006) Treatment of central nervous system degenerative disorders, inGoodman and Gilman's The Pharmacological Basis of Therapeutics,11thed(BruntonL, LazoJ, andParkerK, eds)pp527-545, McGraw-Hill, New York.
352. Stark P and Dews PB (1980) Cannabinoids. I. Behavioral effects. J Pharmacol Exp Ther214:124-130.
353. Stein L and Ray OS (1960) Brain stimulation reward"thresholds"self-determined in rat. Psychopharmacology (Berl)1:251-256.
354. Stellar JR and Rice MB (1989) Pharmacological basis of intracranial self-stimulation reward, inThe Neuropharmacological Basis of Reward(Liebman JM and Cooper SJ, eds) pp 14-65, Oxford University Press, New York.
355. Stellar JR and Stellar E (1985)The Neurobiology of Motivation and Reward, Springer-Verlag, New York.
356. Stoker AK and Markou A(2011a) The intracranial self-stimulation procedure provides quantitative measures of brain reward function, inMood and Anxiety Related Phenotypes in MIce: Characterization Using Behavioral Tests, Volume II. Neuromethods Volume 63(Gould TD, ed) pp 307-331, Humana Press, Totowa, NJ.
357. Stoker AK and Markou A (2011b) Withdrawal from chronic cocaine administration induces deficits in brain reward function in C57BL/6J mice. Behav Brain Res223: 176-181.
358. Stratmann JA and Craft RM (1997) Intracranial self-stimulation in female and male rats: no sex differences using a rate-independent procedure. Drug Alcohol Depend 46:31-40.
359. Straub CJ, Carlezon WA Jr, and Rudolph U (2010) Diazepam and cocaine potentiate brain stimulation reward in C57BL/6J mice. Behav Brain Res206:17-20.
360. Strecker RE, Roberts DC, and Koob GF (1982) Apomorphine-induced facilitation of intracranial self-stimulation following dopamine denervation of the nucleus accumbens. Pharmacol Biochem Behav17:1015-1018.
361. Sundstrom JM, Hall FS, Stellar JR, and Waugh EJ (2002) Effects of isolation-rearing on intracranial self-stimulation reward of the lateral hypothalamus: baseline assessment and drug challenges. Life Sci70:2799-2810.
362. TakadaK and Yanagita T (1997) Drug dependence study on vigabatrin in rhesus monkeys and rats. Arzneimittelforschung47:1087-1092.
363. Tang AH and Collins RJ (1985) Behavioral effects of a novel kappa opioid analgesic, U-50488, in rats and rhesus monkeys. Psychopharmacology (Berl)85:309-314.
364. Taylor P (2006a) Agents acting at the neuromuscular junction and autonomic ganglia, inGoodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed (Brunton L, Lazo J, and Parker K, eds) pp 217-236, McGraw-Hill, New York.
365. Taylor P (2006b) Anticholinesterase agents, inGoodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed (Brunton L, Lazo J, and Parker K, eds) pp 201-216, McGraw-Hill, New York.
366. Thompson T and Schuster CR (1964) Morphine self-administration, food-reinforced, and avoidance behaviors in rhesus monkeys. Psychopharmacology (Berl)5:87-94.
367. Tobey KM, Walentiny DM, Wiley JL, Carroll FI, Damaj MI, Azar MR, Koob GF, George O, Harris LS, and Vann RE (2012) Effects of the specifica4b2 nAChR antagonist, 2-fluoro-3-(4-nitrophenyl) deschloroepibatidine, on nicotine rewardrelated behaviors in rats and mice. Psychopharmacology (Berl)223:159-168.
368. Todtenkopf MS, Marcus JF, Portoghese PS, and Carlezon WA Jr (2004) Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl)172:463-470.
369. Tomasiewicz HC, Todtenkopf MS, Chartoff EH, Cohen BM, and Carlezon WA Jr (2008) The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry64:982-988.
370. Tracy ME, Slavova-Hernandez GG, and Shelton KL (2014) Assessment of reinforcement enhancing effects of toluene vapor and nitrous oxide in intracranial self-stimulation. Psychopharmacology (Berl)7: 1339-1350.
371. Trujillo-Pisanty I, Conover K, and Shizgal P (2013) A new view of the effect of dopamine receptor antagonism on operant performance for rewarding brain stimulation in the rat. Psychopharmacology (Berl)doi: 10.1007/s00213-013-3328-x.
372. Tzschentke TM and Schmidt WJ (1999) Memantine does not substantially affect brain stimulation reward: comparison with MK-801. Brain Res845:192-198.
373. Unterwald EM and Kornetsky C (1984) Effects of concomitant pentazocine and tripelennamine on brain-stimulation reward. Pharmacol Biochem Behav21:961-964.
374. Unterwald EM, Kucharski LT, Williams JE, and Kornetsky C (1984) Tripelennamine: enhancement of brain-stimulation reward. Life Sci34:149-153.
375. ValenzanoKJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, and Shan S, et al. (2005) Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology48:658-672.
376. van der Kam EL, De Vry J, and Tzschentke TM (2009) The mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) supports intravenous selfadministration and induces conditioned place preference in the rat. Eur J Pharmacol607:114-120.
377. van der Veen R, Piazza PV, and Deroche-Gamonet V (2007) Gene-environment interactions in vulnerability to cocaine intravenous self-administration: a brief social experience affects intake in DBA/2J but not in C57BL/6J mice. Psychopharmacology (Berl)193:179-186.
378. van Heesch F, Prins J, Konsman JP, Westphal KG, Olivier B, Kraneveld AD, and Korte SM (2013) Lipopolysaccharide-induced anhedonia is abolished in male serotonin transporter knockout rats: an intracranial self-stimulation study. Brain Behav Immun29:98-103.
379. Veening JG, Swanson LW, Cowan WM, Nieuwenhuys R, and Geeraedts LM (1982) The medial forebrain bundle of the rat. II. An autoradiographic study of the topography of the major descending and ascending components. J Comp Neurol206: 82-108.
380. Vlachou S and Markou A (2010) GABABreceptors in reward processes. Adv Pharmacol58:315-371.
381. Vlachou S and Markou A (2011) Intracranial self-stimulation, inAnimal Models of Drug Addiction(Olmstead MC, ed) pp 3-56, Humana Press, New York.
382. Vlachou S, Nomikos GG, and Panagis G (2005) CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. Psychopharmacology (Berl) 179:498-508.
383. Vlachou S, Nomikos GG, and Panagis G (2006) Effects of endocannabinoid neurotransmission modulators on brain stimulation reward. Psychopharmacology (Berl) 188:293-305.
384. Vlachou S, Nomikos GG, Stephens DN, and Panagis G (2007) Lack of evidence for appetitive effects of Delta 9-tetrahydrocannabinol in the intracranial selfstimulation and conditioned place preference procedures in rodents. Behav Pharmacol18:311-319.
385. Vlachou S and Panagis G (2014) Regulation of brain reward by the endocannabinoid system: a critical review of behavioral studies in animals. Curr Pharm Des20: 2072-2088.
386. Vlachou S, Paterson NE, Guery S, Kaupmann K, Froestl W, Banerjee D, Finn MG, and Markou A (2011) Both GABA(B) receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats. Eur J Pharmacol655:52-58.
387. Volkow ND, Wang GJ, Fowler JS, and Tomasi D (2012) Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol52:321-336.
388. Wang Z and Woolverton WL (2007) Estimating the relative reinforcing strength of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacology (Berl)189: 483-488.
389. Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, Marusich JA, Wegner S, and Olive MF (2014) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol19:165-174.
390. Wauquier A and Niemergeers CJ (1974) Intracranial self-stimulation in rats as a function of various stimulus parameters. V. Influence of cocaine on medial forebrain bundle stimulation with monopolar electrodes. Psychopharmacology (Berl) 38:201-210.
391. Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, and Woolverton WL (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther313:848-854.
392. Wee S and Woolverton WL (2006) Self-administration of mixtures of fenfluramine and amphetamine by rhesus monkeys. Pharmacol Biochem Behav84:337-343.
393. Weed MR, Vanover KE, and Woolverton WL (1993) Reinforcing effect of the D1 dopamine agonist SKF 81297 in rhesus monkeys. Psychopharmacology (Berl)113: 51-52.
394. WeeksJR (1962) Experimental morphine addiction: method for automatic intravenous injections in unrestrained rats. Science138:143-144.
395. Wellman PJ, Clifford PS, Rodriguez JA, Hughes S, Di Francesco C, Melotto S, Tessari M, Corsi M, Bifone A, and Gozzi A (2012) Brain reinforcement system function is ghrelin dependent: studies in the rat using pharmacological fMRI and intracranial self-stimulation. Addict Biol17:908-919.
396. West CH, Schaefer GJ, and Michael RP (1983) Increasing the work requirements lowers the threshold of naloxone for reducing self-stimulation in the midbrain of rats. Pharmacol Biochem Behav18:705-710.
397. Westfall TC and Westfall DP (2006) Adrenergic agonists and antagonists, inGoodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed (Brunton L, Lazo J, and Parker K, eds) pp 237-295, McGraw-Hill, New York.
398. Wiley JL, Marusich JA, and Huffman JW (2014) Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci97:55-63.
399. Willick ML and Kokkinidis L (1995) The effects of ventral tegmental administration of GABAA, GABAB and NMDA receptor agonists on medial forebrain bundle selfstimulation. Behav Brain Res70:31-36.
400. Winger G, Hursh SR, Casey KL, and Woods JH (2002) Relative reinforcing strength of threeN-methyl-D-aspartate antagonists with different onsets of action. JPharmacol Exp Ther301:690-697.
401. Wise RA (1996) Addictive drugs and brain stimulation reward. Annu Rev Neurosci 19:319-340.
402. Wise RA (1998) Drug-activation of brain reward pathways. Drug Alcohol Depend51: 13-22.
403. Wood RI (2004) Reinforcing aspects of androgens. Physiol Behav83:279-289.
404. Wood RI (2008) Anabolic-androgenic steroid dependence? Insights from animals and humans. Front Neuroendocrinol29:490-506.
405. Woolverton WL, Goldberg LI, and Ginos JZ (1984) Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. JPharmacolExpTher230:678-683.
406. Woolverton WL, Wessinger WD, and Balster RL (1982) Reinforcing properties of clonidine in rhesus monkeys. Psychopharmacology (Berl)77:17-23.
407. Yanagita T (1978) Drug dependence studies in laboratory animals. NIDA Res Monogr 19:179-190.
408. Yeomans J, Forster G, and Blaha C (2001) M5 muscarinic receptors are needed for slow activation of dopamine neurons and for rewarding brain stimulation. Life Sci68:2449-2456.
409. Yeomans JS (1989) Two substrates for medial forebrain bundle selfstimulation: myelinated axons and dopamine axons. Neurosci Biobehav Rev13: 91-98.
410. You ZB, Chen YQ, and Wise RA (2001) Dopamine and glutamate release in the nucleus accumbens and ventral tegmental area of rat following lateral hypothalamic self-stimulation. Neuroscience 107: 629-639.